Abstract:Holly A Maulhardt, 1 Alyson M Marin, 1 Gere S diZerega 1, 2 1 US Biotest, Inc, San Luis Obispo, CA, USA; 2 Nanology, LLC, Fort Worth, TX, USA Correspondence: Gere S diZerega, US Biotest, Inc, 231 Bonetti Drive, Suite 240, San Luis Obispo, CA, 93401, USA, Tel +01 805 595 1300, Email The effects of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) alone and in combination with systemic administration of the programmed cell death protein antibody (anti-mPD-1) were evaluated in a syngeneic murine model of melanoma. Groups of mice with subcutaneously implanted Clone M3 (Cloudman S91) tumors were treated with single and combination therapies. Tumor volume (TV) measurements, body weights, and clinical observations were followed in-life. At end of study, tumor-site tissues were collected, measured, and processed for flow cytometry along with blood and lymph nodes. The combination of LSAM-PTX + anti-mPD-1 resulted in an antitumoral response, which produced a significant decrease in TV compared to control animals. TV decreases also occurred in the LSAM-PTX and anti-mPD-1 groups. Flow cytometry analysis found increases in granulocytes and M2 macrophages and decreases in dendritic cells (DC) and monocytic myeloid-derived suppressor cells (M-MDSC) in tumor-site tissues. Increases in granulocytes and decreases in CD4+ T cells, macrophages, and M1 macrophages were found in the blood of animals administered the combination treatment. Increases in natural killer (NK) cells were found in lymph node tissue in the combination treatment group. These findings suggest that IT LSAM-PTX may provide benefit in the local treatment of melanomas and may synergize with systemic anti-PD-1 therapy, leading to additional tumoricidal outcomes without added systemic toxicity. Keywords: clone M-3, nanopac, combinatorial immunotherapy, PD-1 Combinations of immune checkpoint blockade with chemotherapy, targeted, oncolytic, or anti-angiogenic treatments have shown encouraging results. 1–4 Transdermal drug delivery systems, such as liposomes, micelles, hydrogels, and emulsions, can facilitate skin permeation and deposition resulting in continuous tumor cell drug exposure. 3,5,6 The approval of talimogene laherparepvec, an attenuated herpesvirus expressing human granulocyte-macrophage colony-stimulating factor (huGM-CSF), for the intralesional treatment of cutaneous, subcutaneous, and nodal lesions established intratumoral (IT) therapy for melanoma treatment. 7 Previously, we reported that IT administration of large surface area microparticle docetaxel (LSAM-DTX) reduced primary and metastatic orthotopic breast cancer in a syngeneic mouse model and anti-tumor activity was further enhanced by addition of systemic treatment with the cytotoxic T lymphocyte antigen 4 antibody (anti-mCTLA-4). 8 This report describes the synergistic reduction in a murine melanoma tumor model (Clone M-3 (Cloudman S91)) following IT administration of a large surface area microparticle paclitaxel (LSAM-PTX) in combination with systemic administration of the programmed cell death protein 1 antibody (anti-mPD-1). LSAM-DTX and LSAM-PTX are investigational products not yet approved for use by the US Food and Drug Administration. The long residence time of LSAM-PTX within the tumor acts as a drug depot, resulting in continuous release of paclitaxel, exposing tumor cells to high, therapeutic levels of chemotherapeutic for several weeks. 9 In addition to the tumoricidal effects of local LSAM-PTX and LSAM-DTX therapy, immunomodulation, including increases in the concentration of innate and adaptive immune cells in the tumor and peripheral blood have also been reported in early-phase clinical studies. 9–12 Immune modulation has also been found in preclinical investigations including increases in immune effector cells in the peripheral blood following LSAM-DTX injections into mouse models of renal (Renca tumors) 13 and breast cancer (4T-1 tumors). 8 In this study, local LSAM-PTX alone and in combination with systemic anti-mPD-1 was evaluated for efficacy and immunomodulation in a syngeneic murine orthotopic melanoma model. Female DBA/2N mice (DBA/2NCrl, Charles River GmbH, Sulzfeld, Germany) were 5 to 10 weeks old on study Day 0. Animals were fed ad libitum water and V1126-000 Complete Feed (ssniff Spezialdiäten GmbH, Soest, Germany) and housed maximum 4/ventilated cage on a 12-h light cycle at 22 ± 2°C/45–65% humidity. Daily monitoring for clinical signs and abnormalities and three-time weekly weighing occurred for the duration of the study. Deviations of the health status of the animals were documented, and animals were euthanized individually before study termination when ethical abortion criteria were reached -Abstract Truncated-

Targeting of M2 macrophages with IL-13-functionalized liposomal prednisolone inhibits melanoma angiogenesis in vivo

Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment

Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages

Multi-Responsive Liposomal Nanocomplex Encapsulating Ce6 & MMP-2 Inhibitors for Photodynamic-Immune Synergistic Treatment of Melanoma

235 IL-4/13 Blocking Peptide (KROS-401) Inhibits M2 Macrophage Polarization in vitro and Demonstrates Anti-tumor Activity in a Murine Model of Glioblastoma

Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy

Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition

A Polymer–lipid Membrane Artificial Cell Nanocarrier Containing Enzyme–oxygen Biotherapeutic Inhibits the Growth of B16F10 Melanoma in 3D Culture and in a Mouse Model

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma

Tumor Microenvironment Remodeling And Tumor Therapy Based On M2-Like Tumor Associated Macrophage-Targeting Nano-Complexes

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion

NIMG-48. TLR7/8-AGONIST-LOADED NANOPARTICLES REPROGRAM TUMOR-ASSOCIATED MYELOID CELLS FOR EFFECTIVE IMMUNOTHERAPY OF EXPERIMENTAL GLIOMA AND MRI-BASED TREATMENT MONITORING

Activating a collaborative innate-adaptive immune response to control breast and ovarian cancer metastasis

Biomimetic manganese-eumelanin nanocomposites for combined hyperthermia-immunotherapy against prostate cancer

In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy

Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy

Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy

Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex